VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Updates on the use of momelotinib for the treatment of MF & clinical trials evaluating this agent

In this video, Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, shares some recent updates on the use of momelotinib for the treatment of myelofibrosis (MF) and clinical trials evaluating this agent. Dr Mesa also highlights the potential FDA approval of this agent in 2023, and shares his thoughts on the future role of momelotinib in the MF treatment landscape. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research funding: Genentech, Promedior, Samus, Gilead, Celgene, Novartis, Constellation Pharmaceuticals, CTI, Abbvie, Sierra Oncology, Incyte Corproation; Consultancy: Novartis, Sierra Oncology, Pharma, Constellation Pharmaceuticals, AOP, La Jolla Pharma, Incyte Corporation.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter